Abstract: Provided are a piperidine derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for the prevention or treatment of diseases related to autotaxin activity, comprising same as an active ingredient, in which the piperidine derivative compound exhibits excellent inhibitory activity against autotaxin, and thus can be effectively used in the treatment and prevention of diseases related to autotaxin inhibition, such as fibrotic diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, metabolic diseases, cancer and cancer metastasis, ocular diseases, cholestatic form and other forms of chronic pruritus, and acute or chronic organ transplant rejection.

Abstract: Provided are a piperidine derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for the prevention or treatment of diseases related to autotaxin activity, comprising same as an active ingredient, in which the piperidine derivative compound exhibits excellent inhibitory activity against autotaxin, and thus can be effectively used in the treatment and prevention of diseases related to autotaxin inhibition, such as fibrotic diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, metabolic diseases, cancer and cancer metastasis, ocular diseases, cholestatic form and other forms of chronic pruritus, and acute or chronic organ transplant rejection.

Abstract: Provided is a 2-cyanopyrimidin-4-yl carbamate or urea derivative or pharmaceutically acceptable salt thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 2-cyanopyrimidin-4-yl carbamate or urea derivative or pharmaceutically acceptable salt thereof selectively inhibits cathepsin K and therefore can be usefully applied for preventing or treating osteoporosis.

Abstract: Provided is a 2-cyanopyrimidin-4-yl carbamate or urea derivative or pharmaceutically acceptable salt thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 2-cyanopyrimidin-4-yl carbamate or urea derivative or pharmaceutically acceptable salt thereof selectively inhibits cathepsin K and therefore can be usefully applied for preventing or treating osteoporosis.

Abstract: A method of improving quality of experience (QoE) in a first device which shares a screen of the first device with a second device includes: detecting a class of a content currently displayed on the screen; determining a QoE policy based on the detected class of the content; encoding a screen image of the screen based on the determined QoE policy; and transmitting the encoded screen image to the second device. As such, when a screen is shared among a plurality of devices, optimal QoE may be achieved with respect to each class of a content.

Abstract: Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11?-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11?-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human-derived 11?-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LADA), insulin tolerance syndromes, obesity, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

Abstract: A method of improving quality of experience (QoE) in a first device which shares a screen of the first device with a second device includes: detecting a class of a content currently displayed on the screen; determining a QoE policy based on the detected class of the content; encoding a screen image of the screen based on the determined QoE policy; and transmitting the encoded screen image to the second device. As such, when a screen is shared among a plurality of devices, optimal QoE may be achieved with respect to each class of a content.

Abstract: Provided is a magnetic device using permanent magnets according to an exemplary embodiment of the present invention. In more detail, the present invention relates to a magnetic device using permanent magnets that can form a high magnetic field using a first permanent magnet and a second permanent magnet to perform various kinds of magnetic field application experiments, in particular, can be used for a single crystal growth, generation of polarized neutrons, and the like, and easily manufactured with a simple configuration and secure sufficient durability.

Abstract: Provided is a magnetic device using permanent magnets according to an exemplary embodiment of the present invention. In more detail, the present invention relates to a magnetic device using permanent magnets that can form a high magnetic field using a first permanent magnet and a second permanent magnet to perform various kinds of magnetic field application experiments, in particular, can be used for a single crystal growth, generation of polarized neutrons, and the like, and easily manufactured with a simple configuration and secure sufficient durability.

Abstract: The invention relates to an electro-optrode neural interface, comprising an optical fiber which is elongated so as to be insertable into a body, and which is located at a core portion so as to form an optical electrode portion, and a liquid crystal polymer(LCP) sample encircling the optical fiber. The LCP sample has an adhesive sheet, and an LCP electrode layer encircling the adhesive sheet, wherein the adhesive sheet and the LCP electrode layer are coupled to each other. The electro-optrode neural interface is formed by combining into a single unit, an electrical interface in which an electrode for stimulating deep brain or measuring neural signals from deep brain is arranged in a liquid crystal polymet and an optical interface such as an optical fiber, a waveguide and an endoscope.

Abstract: Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11?-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11?-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human-derived 11?-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LADA), insulin tolerance syndromes, obesity, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.